Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
Bo ChengKaikai DingPengxiang ChenJianxiong JiTao LuoXiaofan GuoWei QiuChunhong MaXue MengJian WangJin-Ming YuYuan LiuPublished in: Cancer communications (London, England) (2022)
Lung cancer patients with poor lymphocyte recovery and suffering from persistent lymphopenia after previous chemotherapy are resistant to anti-PD-1/PD-L1 antibodies but might be sensitive to second-generation agents such as SHR-1701.